Martha Gomez, MD
Endocrinology, Diabetes & Metabolism · San Juan, PRNPI 1003822651
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,451 of the $11,988 with a category attached, or 70.5%. 15 manufacturers reported payments, led by Eli Lilly at 29.7% of the total. Reporting peaked in 2019 at $3,643 and has fallen 81.7% since, to $668 in 2025.
Across 396 payments — averaging $30.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$4K
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- Sanofi-aventis U.S. LLC$1K
- Novo Nordisk$1K
- Eli Lilly Export S.A. Puerto Rico Branch$807
- plus $2K from 9 others
Across 85 payments — averaging $60,985 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly Export S.A. Puerto Rico Branch$4.8M
- Eli Lilly$385K
What the payments were for
- Speaking & faculty fees$3003%
- Travel & lodging$3,22627%
- Food & beverage$8,45170%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 26 | $3,557 |
| AstraZeneca | 75 | $1,518 |
| Boehringer Ingelheim | 62 | $1,450 |
| Sanofi-aventis U.S. LLC | 40 | $1,373 |
| Novo Nordisk | 56 | $1,165 |
| Eli Lilly Export S.A. Puerto Rico Branch | 43 | $807 |
| Merck | 27 | $591 |
| Abbott | 22 | $438 |
| Johnson & Johnson | 19 | $415 |
| AbbVie | 8 | $181 |
| Dexcom, Inc. | 7 | $138 |
| Medtronic | 2 | $117 |
| Lilly USA, LLC | 4 | $106 |
| Radius Health, Inc. | 3 | $96 |
| Amgen | 2 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOTAGLIFLOZIN$300
- SOLIQUA 100/33$126
- TOUJEO$126
- LANTUS$126
- FARXIGA$124
- JARDIANCE$121
How this compares
$11,988 in reported general payments places this provider in the 80th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
See all endocrinology, diabetes & metabolism providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 355 | $279,932 |
| OzempicSemaglutide | 204 | $203,955 |
| TrulicityDulaglutide | 145 | $183,788 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 182 | $127,350 |
| SynthroidLevothyroxine Sodium | 1,090 | $95,459 |
| JanuviaSitagliptin Phosphate | 120 | $95,242 |
| MounjaroTirzepatide | 79 | $90,679 |
| FarxigaDapagliflozin Propanediol | 79 | $69,300 |
| Xigduo XrDapaglifloz Propaned/Metformin | 84 | $59,577 |
| ProliaDenosumab | 32 | $56,034 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 79 | $52,941 |
| RybelsusSemaglutide | 48 | $52,302 |
| SynjardyEmpagliflozin/Metformin Hcl | 95 | $35,915 |
| Humalog Kwikpen U-200Insulin Lispro | 28 | $25,405 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $23,684 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Tradjenta | $1,450 | $463,514659 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog Mix 75-25, Humalog, Humulin 70-30 | $106 | $300,800402 claims |
| Novo NordiskOzempic, Rybelsus | $1,165 | $256,257252 claims |
| MerckJanuvia, Janumet Xr, Janumet | $591 | $134,320156 claims |
| AbbVieSynthroid | $181 | $95,4591,090 claims |
| AstraZenecaFarxiga | $1,518 | $69,30079 claims |
| AmgenProlia | $35 | $56,03432 claims |
| Sanofi-aventis U.S. LLCLantus | $1,373 | $13,394126 claims |
| Johnson & JohnsonXarelto | $415 | $8,55915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
Other endocrinology, diabetes & metabolism in San Juan
- Manuel Alegre-HernandezSan Juan$156K
- Monica Ortiz-RiveraSan Juan$148K
- Alex Gonzalez BossoloSan Juan$110K
- Michelle Mangual GarciaSan Juan$87K
- Meliza Martinez RodriguezSan Juan$80K
- Jorge de Jesus MirandaSan Juan$30K
- Zahira Lugo LopezSan Juan$29K
- Oscar Ruiz BermudezSan Juan$27K
- Margarita Ramirez-VickSan Juan$15K
- Yanira Marrero McFalineSan Juan$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.